Cerenis wins €2.5M from OSEO

Funding

Cerenis Therapeutics SA has received €2.5 million from OSEO, the state-backed company that provides financial support to French start-ups. The money will finance the clinical development of Cerenis’ portfolio of cardiovascular and metabolic diseases treatments.

The financing will support continued development of the company's CER-001 programme, enabling the company to apply for permission to conduct a clinical trial

“This new source of funding will support our efforts to advance [CER-001] through the Investigational New Drug approval process and onto clinical development,” said Jean-Louis Dasseux, president and CEO. “We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market.”